BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

Search

Argenx SE

Open

BrancheGesundheitswesen

532 0.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

523.6

Max

534.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

751M

836M

Verkäufe

730M

1.3B

KGV

Branchendurchschnitt

46.72

57.333

EPS

0.72

Gewinnspanne

64.112

Angestellte

1,599

EBITDA

37M

126M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-2.07% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.3B

32B

Vorheriger Eröffnungskurs

531.39

Vorheriger Schlusskurs

532

Argenx SE Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Apr. 2025, 23:44 UTC

Heiße Aktien

Stocks to Watch: Jacobs Solutions, Argenx

10. Apr. 2025, 23:39 UTC

Wichtige Markttreiber

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

Peer-Vergleich

Kursveränderung

Argenx SE Prognose

Kursziel

By TipRanks

-2.07% Nachteil

12-Monats-Prognose

Durchschnitt 438.33 EUR  -2.07%

Hoch 545 EUR

Tief 223 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Argenx SE – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

5

Buy

0

Halten

1

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.